Macrogenics (MGNX) EBIT (2012 - 2026)

Macrogenics (MGNX) has 15 years of EBIT data on file, last reported at -$33.4 million in Q1 2026.

• On a quarterly basis, EBIT rose 21.55% year-over-year to -$33.4 million in Q1 2026; TTM through Mar 2026 was -$63.7 million, a 35.99% increase from a year earlier, with the FY2025 full-year figure at -$72.8 million, up 34.13% from the prior year.
• EBIT for Q1 2026 stood at -$33.4 million, down from -$12.1 million in the prior quarter.
• Over the last five years, EBIT for MGNX reached as high as $54.2 million in Q3 2024 and fell as low as -$66.6 million in Q1 2022.
• Historically, EBIT has averaged -$29.8 million across 5 years, with a median of -$38.4 million in 2023.
• Across the five-year window, EBIT slumped 511.87% in 2023 and jumped 252.64% in 2024, its largest moves.
• Year by year, EBIT stood at $12.0 million in 2022, then slumped by 511.87% to -$49.4 million in 2023, then declined by 7.06% to -$52.8 million in 2024, then soared by 77.11% to -$12.1 million in 2025, then slumped by 176.42% to -$33.4 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$33.4 million in Q1 2026, -$12.1 million in Q4 2025, and $18.6 million in Q3 2025.